華東醫藥(000963.SZ):中美華東擬3.7億元對荃信生物進行股權投資 雙方已簽訂產品合作開發協議
格隆匯 8 月 17日丨華東醫藥(000963.SZ)公佈,2020年8月14日,公司全資子公司中美華東與荃信生物在杭州共同簽訂了相關股權投資協議和產品合作開發協議(簡稱《合作協議》)。根據股權投資協議約定,中美華東將通過增資形式出資3.7億元對荃信生物進行股權投資,投資完成後持有其20.56%股權,成為其第二大股東;根據產品合作開發協議,雙方將就荃信生物在研的QX001S產品(原研藥Stelara (烏司奴單抗)的生物類似藥,用於治療銀屑病、克羅恩病等)在中國大陸境內進行合作開發和商業化,並在產品上市後按照協議約定分享收益。公司董事會審議通過了本次交易並授權公司董事長簽署了相關合作協議。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.